IL17A and colitis: Tarhini et al. assessed candidate circulating factors which were associated with irAEs in melanoma patients treated with ipilimumab as a neoadjuvant therapy and revealed that circulating IL-17 levels at baseline significantly correlated with the incidence of grade 3 irAEs of diarrhea/colitis (153).